MedPath

Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps

Not yet recruiting
Conditions
Heart Failure
Registration Number
NCT06765226
Lead Sponsor
Abiomed Inc.
Brief Summary

Analysis of cell and protein deposits on the Impella Heart Pump.

Detailed Description

The Impella heart pump supports patients in cardiogenic shock for various reasons and has passed safety and biocompatibility evaluations. The planned investigation aims to further analyze cell and protein adhesion on these pumps and the effects of their prolonged use, especially in scenarios like bridge-to-transplant, recognizing preclinical testing limitations.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Patients with Impella 5.5 therapy and duration of support for ≥ 25 days OR Patients with Impella CP therapy and duration of support for > 4 days
  • Use of Sodium Bicarbonate as a purge additive as permitted by the IFU
Exclusion Criteria
  • Age < 18 years

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Investigate deposits and biomaterial after use of pumpthrough study completion, at least 25 days

investigate Impella 5.5 pumps after use regarding deposits and biomaterial

Secondary Outcome Measures
NameTimeMethod
Relation deposits and biomaterial to clinical eventsthrough study completion, at least 25 days

By correlating patient data, such as medical history and Impella 5.5 related blood parameters, with the findings from our pump analysis, potential connections between medication, diseases, comorbidities, and deposits on the pump can be identified.

Trial Locations

Locations (2)

Herzzentrum Dresden

🇩🇪

Dresden, Saxony, Germany

Deutsches Herzzentrum der Charité Berlin

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath